4 December 2013 - Cell Therapeutics, Inc. announced today that it concluded an agreement with the National Association of Statutory Health Insurance Funds (GKV-Spitzenverband) in Germany for Pixuvri (pixantrone).  Pixuvri is the first medicinal product approved in the European Union for patients with aggressive B-cell non-Hodgkin lymphoma who have failed two or three prior lines of therapy.

For more details, go to: http://investors.celltherapeutics.com/phoenix.zhtml?c=92775&p=irol-newsArticle&cat=news&id=1881746